Soquelitinib

Phase 3Small molecule

CCorvus Pharmaceuticals, Inc.

Soquelitinib is one of 36 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Lymphoproliferative SyndromeActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Lymphoproliferative SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Lymphoproliferative Syndrome

NCT06730126

Q3 2027

Phase 2Recruiting

ART

NCT07441395

Q3 2028

Phase 3Recruiting

Lymphoma

NCT06561048

Clinical

Trials by Indication[1]

ART1 trial

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Recruiting·CCorvus Pharmaceuticals, Inc.·Phase 2·NCT07441395·200 enrolled

Lymphoproliferative Syndrome1 trial

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06730126·15 enrolled

Lymphoma1 trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Recruiting·CCorvus Pharmaceuticals, Inc.·Phase 3·NCT06561048·150 enrolled

Efficacy1 trial

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Completed·CCorvus Pharmaceuticals, Inc.·Phase 1·NCT06345404·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Soquelitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Soquelitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Soquelitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corvus Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCorvus Pharmaceuticals, Inc.

Soquelitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q3 2028

Trials by Indication[1]

ART1 trial

Lymphoproliferative Syndrome1 trial

Lymphoma1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News